DaVita reports Q4 adjusted EPS $2.24, consensus $2.15

Reports Q4 revenue $3.3B, consensus $3.27B. The company said, “Despite a year with unique hurdles, we finished strong in 2024, producing full year adjusted operating income and adjusted EPS in the top half of our guidance range. As we embark on 2025, when we will be celebrating the 25th anniversary of DaVita (DVA), we look forward to continuing our efforts to improve clinical outcomes, enhance quality of life for our patients and teammates, and be a force for positive change in the healthcare system.”